[HTML][HTML] Strategies to stabilize compact folding and minimize aggregation of antibody-based fragments
Monoclonal antibodies (mAbs) have proven to be useful for development of new therapeutic
drugs and diagnostic techniques. To overcome the difficulties posed by their complex …
drugs and diagnostic techniques. To overcome the difficulties posed by their complex …
Engineered antibody fragments and the rise of single domains
P Holliger, PJ Hudson - Nature biotechnology, 2005 - nature.com
With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
Computational design to reduce conformational flexibility and aggregation rates of an antibody fab fragment
Computationally guided semirational design has significant potential for improving the
aggregation kinetics of protein biopharmaceuticals. While improvement in the global …
aggregation kinetics of protein biopharmaceuticals. While improvement in the global …
David vs. Goliath: the structure, function, and clinical prospects of antibody fragments
A Bates, CA Power - Antibodies, 2019 - mdpi.com
Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies
have become the largest class of biopharmaceuticals with over 80 antibodies currently …
have become the largest class of biopharmaceuticals with over 80 antibodies currently …
Antibody aggregation: insights from sequence and structure
Monoclonal antibodies (mAbs) are the fastest-growing biological therapeutics with important
applications ranging from cancers, autoimmunity diseases and metabolic disorders to …
applications ranging from cancers, autoimmunity diseases and metabolic disorders to …
Antibody therapeutics, antibody engineering, and the merits of protein stability.
SJ Demarest, SM Glaser - Current opinion in drug discovery & …, 2008 - europepmc.org
Antibodies are highly soluble, multidomain proteins that are well suited for
biopharmaceutical development; however, engineering antibodies to perform novel …
biopharmaceutical development; however, engineering antibodies to perform novel …
Applications of single-chain variable fragment antibodies in therapeutics and diagnostics
NE Weisser, JC Hall - Biotechnology advances, 2009 - Elsevier
Antibodies (Abs) are some of the most powerful tools in therapy and diagnostics and are
currently one of the fastest growing classes of therapeutic molecules. Recombinant antibody …
currently one of the fastest growing classes of therapeutic molecules. Recombinant antibody …
Aggregation, stability, and formulation of human antibody therapeutics
D Lowe, K Dudgeon, R Rouet, P Schofield… - Advances in protein …, 2011 - Elsevier
Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …
stability and a propensity to aggregate. These unfavorable tendencies can be even more …
Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies
SV Thakkar, N Sahni, SB Joshi, BA Kerwin… - Protein …, 2013 - Wiley Online Library
Aggregation of monoclonal antibodies is often a multi‐step process involving structural
alterations in monomeric proteins and subsequent formation of soluble or insoluble …
alterations in monomeric proteins and subsequent formation of soluble or insoluble …
New protein engineering approaches to multivalent and bispecific antibody fragments
A Plückthun, P Pack - Immunotechnology, 1997 - Elsevier
Multivalency is one of the hallmarks of antibodies, by which enormous gains in functional
affinity, and thereby improved performance in vivo and in a variety of in vitro assays are …
affinity, and thereby improved performance in vivo and in a variety of in vitro assays are …